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Pur-alpha functionally interacts with FUS carrying
ALS-associated mutations
M Di Salvio1,2, V Piccinni1,2, V Gerbino3, F Mantoni1,2, S Camerini4, J Lenzi5, A Rosa2, L Chellini6, F Loreni6, MT Carrì3,6, I Bozzoni2,5,
M Cozzolino*,3,7 and G Cestra*,1,2
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder due to motor neuron loss. Fused in sarcoma (FUS) protein
carrying ALS-associated mutations localizes to stress granules and causes their coalescence into larger aggregates. Here we show
that Pur-alpha physically interacts with mutated FUS in an RNA-dependent manner. Pur-alpha colocalizes with FUS carryingmutations
in stress granules of motoneuronal cells differentiated from induced pluripotent stem cells and that are derived from ALS patients.
We observe that both Pur-alpha and mutated FUS upregulate phosphorylation of the translation initiation factor eukaryotic translation
initiation factor 2 alpha and consistently inhibit global protein synthesis. In vivo expression of Pur-alpha in different Drosophila tissues
significatively exacerbates the neurodegeneration caused by mutated FUS. Conversely, the downregulation of Pur-alpha in neurons
expressing mutated FUS significatively improves fly climbing activity. All these findings suggest that Pur-alpha, through the control
of mRNA translation, might be involved in the pathogenesis of ALS associated with the mutation of FUS, and that an alteration
of protein synthesis may be directly implicated in the disease. Finally, in vivo RNAi-mediated ablation of Pur-alpha produced
locomotion defects in Drosophila, indicating a pivotal role for this protein in the motoneuronal function.
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Amyotrophic lateral sclerosis (ALS) is a severe neurodegen-
erative disorder caused by motor neuron loss in the brain
and spinal cord.1 Several gene mutations are causative of
the familiar form of the disease and the corresponding mutant
proteins often mislocalize and aggregate in the cytoplasm.
This is the case of fused in sarcoma/translocated in
liposarcoma (FUS/TLS or FUS).2,3 FUS is a nuclear DNA/
RNA-binding protein that contains nuclear import and export
signals and regulates transcription, splicing, and mRNA
metabolism.1 In familiar ALS FUS mutations often map
in the C-terminal proline/tyrosine-nuclear localization signal
(PY-NLS).4,5 While wild-type FUS localizes in the nucleus,
mutant protein often localizes in the cytoplasm, where
eventually coalesces into stress granule (SG) aggregates.6
Mutation in the PY-NLS motif, although resulting in the
abnormal cytosolic localization of FUS, may not be sufficient
for its recruitment in SGs. Therefore, we hypothesize
that alterations of a protein–protein interaction network around
the C-terminus of FUS may account for its localization
in SGs, affecting ALS pathogenesis. By affinity purification
experiments from rat total brain extract, we identified
Pur-alpha as a protein that specifically binds to FUS
C-terminal fragment. Pur-alpha is a highly conserved protein,
which interacts in a sequence-specific manner with single-
stranded DNA and RNA.7 It is involved in targeting mRNA to
neuronal dendrites,8 in DNA replication, DNA repair, and gene
transcription and it associates to the TAR RNA element
of HIV-1.9–11 Pur-alpha knockout mice die within 4 weeks of
major neurological disorders.12 Very interestingly, Pur-alpha
was recently demonstrated to bind to GGGGCC expanded
repeats of C9orf72 gene, which represents the most frequent
mutation associated with familiar ALS.13 In a Drosophila
model of neurodegeneration caused by GGGGCC repeats
expression, Pur-alpha ameliorates the phenotype.14 Here we
provide new evidence for a role of Pur-alpha in the regulation
of translation and SG formation and we suggest that it may be
involved in the pathogenesis of FUS-mediated ALS.
Results
Identification of Pur-alpha as an FUS-binding protein.
To identify the protein–protein interaction network involving
the last 17 residues of FUS we generated glutathione
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S-transferase (GST) fusions of the C-terminus of FUS to use
as bait in affinity purification experiments. We subcloned the
human cDNA encoding the last 51 residues of wild-type FUS
(FUS_Ct_WT), which encompasses a small fragment of the
last RNA-binding domain, to leave enough space between
the GST tag and the C-terminal motif. Then we mutagenized
FUS_Ct_WT construct introducing four ALS-associated
mutations (R521G, R522G, R524S, and P525L) and
we generated a construct named hereafter Multiple Mutant,
MM (FUS_Ct_MM). We used GST-tagged FUS_Ct_WT
and FUS_Ct_MM, and GST on its own in affinity purification
experiments from brain Triton X-100 extracts. By nanoflow
reversed-phase liquid chromatography tandem mass
spectrometry we identified several FUS-binding partners.
We found interactors that bind FUSWT fragment, but less
efficiently FUSMM, and proteins that showed an increased
affinity for mutated FUS.
Although we utilized only a small fragment of FUS of
51 amino acids as bait, we were able to identify 24 putative
binding partners that differentially interact with one or
another of the two forms of the C-terminal peptide. Among
all these partners PABP and NonA, involved in SG and
paraspeckle formation respectively,2,15 were already known
as FUS-binding proteins. Of these 24 partners we found
7 RNA-binding proteins, 5 mRNA translation regulators,
4 DNA-binding proteins involved in transcriptional control,
4 proteins involved in microtubule assembly, and 4 interactors
either with an unknown function or involved in cell signaling
and mitochondrial regulatory activity.
Among interactors that bind strongly mutated FUS motif we
directed our attention on Pur-alpha. To characterize the
interaction between FUS C-terminal region and Pur-alpha,
GST fragments were incubated with a Triton X-100 extract
from rat brain, with or without RNAse. As shown in Figure 1a
(left panel), Pur-alpha binds preferentially FUSMM and to
a minor extent FUSWT. The interaction is almost completely
abolished by RNAse treatment (right panel). FUS/Pur-alpha
interaction was also confirmed in a pull-down assay in which
GST FUS fragments were incubated with in vitro-translated
hemagglutin (HA)-tagged Pur-alpha (Figure 1b).
To isolate a stable complex containing both full-length
proteins, and to analyze binding activity of the singlemutations
of FUS to Pur-alpha, we immunoprecipitated FUS from HeLa
cells co-expressing each Flag-FUS mutant with HA-Pur-
alpha. As indicated in Figure 1c, while R522G, P525L, and
FUSMM show a robust interaction with Pur-alpha, FUSWT,
R521G, and R524S bind very weakly.
Pur-alpha colocalizes with FUS protein carrying ALS-
associated mutations. We transfected HeLa and NSC-34
(data not shown) cells with Flag-FUSWT or Flag-FUSMM
and we visualized, by immunofluorescence, endogenous
Pur-alpha in transfected and untransfected cells (Figure 2a).
Since FUS mutants often relocalize in the cytoplasm
where it coalesce into SGs, we studied FUS and Pur-alpha
localization compared with the SG marker TIAR (TIA-1 related
protein). Pur-alpha, which is distributed in both nuclear and
cytoplasmic compartments, showed a partial co-localization
with FUSWT, which localizes exclusively in the nucleus. In cells
overexpressing FUSMM, which forms large SG aggregates,
Figure 1 FUS/Pur-alpha physical interaction. (a) GST, GST-fused C-terminal
region of wild-type FUS (FUS_Ct_WT), and GST C-terminal domain of multimutated
FUS (FUS_Ct_MM) were used as baits in affinity purification experiments from a rat
brain Triton X-100 extract, in the presence or absence of RNAse. Affinity-purified
material retained by the GST fusion proteins was resolved by SDS-PAGE and
processed by western blotting with anti-Pur-alpha antibody (top). The same volume of
eluted material analyzed by western blotting was separated on a different SDS-PAGE
and stained with Coomassie blue to verify equal loading of the different GST fusion
baits (bottom). 1 : 500 of total brain extract and 1:50 of proteins retained from each
column were loaded on the gel. SM, starting material. (b) Interaction between the
same GST fusion proteins utilized in (a) and in vitro-translated HA-tagged Pur-alpha
was tested by pull-down in the presence or absence of RNAse. HA Pur-alpha bound
to the GST fusion proteins was resolved by SDS-PAGE and analyzed by western
blotting with anti-HA antibody. GST fusion proteins used in the pull-down assay were
resolved by SDS-PAGE and stained with Coomassie blue (bottom). 1 : 50 of
reticulocyte extract exploited in the pull down and 1:3 of proteins retained from each
column were loaded on the gel. (c) Protein extracts from HeLa cells expressing HA-
Pur-alpha on its own (Control), or together with FUSWT, FUS carrying single
mutations (R521G, R522G, R524S, or P525L), or FUSMM were incubated with or
without RNAse and immunoprecipitated with anti-Flag antibody. Retained proteins
were separated by SDS-PAGE and analyzed by western blotting with anti-HA and
anti-Flag antibodies. 1 : 50 of total cell extract utilized for each immunoprecipitation
and 1 : 3 of bound proteins were loaded on the gel. SM, starting material; IP,
immunoprecipitate
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Pur-alpha strongly colocalizes with FUSMM in cytoplasmic
inclusions (Figure 2a). Pur-alpha behaves as an SG protein
and it strongly relocalizes together with TIAR in cells treated with
the oxidative stress-producing agent sodium arsenite (Figure 2b).
To study the localization of Pur-alpha in cells expressing
single mutation of FUS we performed immunofluorescence
labeling of HeLa cells transfected with plasmids encoding
each Flag-FUS mutant. As shown in Figure 3, FUSWT,
R521G, and R524S, which are distributed almost exclusively
in the nucleus, co-localize with the nuclear pool of Pur-alpha.
Differently, R522G, P525L, and FUSMM, which strongly
relocalize in cytoplasmic aggregates, show a prominent
co-localization with endogenous Pur-alpha. Interestingly, in a
significant population of cells expressing R521G and R524S
mutants, which generate only very small pool of cytoplasmic
protein and rarely form visible aggregates, Pur-alpha and
TIAR relocalize in SGs (Figure 3a). No SGs are observed in
cells expressing FUSWT. Thus Pur-alpha relocalizes in SGs
and strongly colocalizes with those FUS mutants that
prominently aggregate in the cytoplasm.
To characterize FUS aggregations in HeLa cells we
analyzed the endogenous localization of TAR DNA-binding
protein-43 (TDP-43) in cells expressing different FUSmutants.
As shown in Supplementary Figure S1 TDP-43 colocalizes
with FUSWT in the nucleus. In cells with small cytoplasmic
aggregations of FUS R522G or large inclusions of P525L,
TDP-43 does not show any major relocalization in the
cytoplasm. Thus, we do not observe any significant
co-localization of TDP-43 with FUS aggregates.
FUS and Pur-alpha are coexpressed in mouse spinal
cord neurons. To investigate whether Pur-alpha is
expressed in cell types more relevant for ALS, we studied
its localization in mouse spinal cord sections. We stained
by immunofluorescence mouse spinal cord cells with either
anti-Pur-alpha or anti-FUS antibodies together with an
antibody against Neuronal Nuclei protein NeuN, used as a
neuronal marker (Figure 3b). Both Pur-alpha and FUS are
consistently expressed in neuronal cells from the spinal cord.
Furthermore, wild-type FUS and Pur-alpha do not show
major co-localization in neurons: while FUS is enriched in the
nucleus, Pur-alpha accumulates in the cytoplasm.
Pur-alpha colocalizes with FUS mutant proteins in
motoneurons differentiated from induced pluripotent
stem cell lines. To confirm the functional relationship of
Pur-alpha with FUS in a more relevant model system for the
disease, we studied the localization of Pur-alpha in induced
Figure 2 Immunofluorescence staining of FUS and Pur-alpha proteins. (a) Effect of FUSMM expression on endogenous Pur-alpha localization. Untransfected HeLa cells
or cells expressing either Flag-FUSWT or Flag-FUSMM were labeled by immunofluorescence with anti-Pur-alpha, anti-Flag, and with antibodies directed against the stress
granule marker TIAR (bars= 10 μm). (b) Untransfected HeLa cells were treated for 30 min with 1 mM of sodium arsenite and stained by immunofluorescence with anti-Pur-alpha
and anti-TIAR antibodies (bars= 20 μm)
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pluripotent stem cell lines (iPSCs), differentiated into
ventral spinal cord populations containing motoneurons.
In the experimental conditions used, a relevant fraction of
cells differentiates in motoneurons, as assessed by
immunofluorescence staining of the motor neuronal markers
islet1/2 (Supplementary Figure S2). As these cell cultures
can be used to model ALS in vitro,16 we analyzed the
localization of Pur-alpha in motoneurons differentiated from
three different genetic backgrounds (Figures 4a and b): wild
type, R521C heterozygous, or P525L homozygous FUS
mutations. Under standard conditions, wild type and mutant
proteins are primarily accumulated in the nucleus, with the
only exception of FUS-P525L, which shows a significant
cytoplasmic pool (Figure 4a). However, under these
conditions, no aggregates of FUS are observed (Figure 4a).
In cells treated with the oxidative stress-producing agent
sodium arsenite, we observe a major relocalization of
Pur-alpha in SGs (Figure 4b). While localization of wild-type
Figure 3 Co-localization of endogenous Pur-alpha with FUS proteins carrying single ALS-associatedmutations. (a) HeLa cells transfected with plasmids encoding Flag-FUSWT or
FUS carrying the indicated single C-terminal mutationswere stained by immunofluorescence with anti-Pur-alpha, anti-Flag, and anti-TIAR antibodies (bars= 10 μm). (b) Localization of
endogenous FUS and Pur-alpha in mouse spinal cord as demonstrated by the counterstain with antibodies directed against the neuronal marker NeuN (bars= 20 μm)
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FUS is not affected by sodium arsenite, in the P525L mutant
the cytoplasmic pool of FUS strongly relocalizes in SGs,
together with Pur-alpha. Although to a lesser extent, FUS
relocalization is also observed in a subset of R521C mutant
cells (Figure 4b). Thus Pur-alpha strongly colocalizes with
cytoplasmic aggregates of mutated FUS.
Pur-alpha and mutated FUS promote eukaryotic
translation initiation factor 2 alpha phosphorylation and
abolish incorporation of puromycin. Untranslated mRNAs
localize to SGs in cells exposed to environmental stress.17,18
Phosphorylation of eukaryotic translation initiation factor
2 alpha (eIF2-alpha), inhibiting translational initiation, allows
elongating ribosomes to run off mRNAs, which accumulate
in SGs. eIF2-alpha phosphorylation is commonly used
as a biochemical marker of SG formation. Thus we
investigated the involvement of Pur-alpha in the regulation
of SG formation analyzing the degree of eIF2-alpha
phosphorylation in cells expressing Pur-alpha and FUS.
Cells transfected with FUSMM or with Pur-alpha show
a significant increase of eIF2-alpha phosphorylation
compared with untransfected cells or cells expressing
FUSWT (Figure 5). To confirm the role of Pur-alpha and
FUSMM in the regulation of mRNA translation we measured
rates of global protein synthesis, through a puromycin
incorporation assay, in cells expressing both proteins.
Figure 4 Co-localization of Pur-alpha with mutated FUS in motoneurons differentiated from IPSCs. (a) Untreated motoneurons differentiated from IPSC cells, which derived
from ALS patients or from healthy donor (WT), were labeled by immunofluorescence with anti-Pur-alpha and anti-FUS antibodies (bars= 10 μm). (b) Same motoneurons shown
in (a) were treated with 0.5 mM of sodium arsenite for 90 min to induce the formation of stress granules and stained by immunofluorescence with anti-Pur-alpha and anti-FUS
antibodies (bars= 10 μm)
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Puromycin works as analogous of aminoacyl-tRNA and
causes premature release of polypeptide chains with
formation of polypeptidyl-puromycin derivatives. Thus the
incorporation rate of puromycin directly reflects
protein synthesis activity.19,20 We treated transfected and
untransfected HeLa cells with puromycin and we followed
its incorporation by immunofluorescence using an
anti-puromycin antibody. As shown in Figure 6a, untrans-
fected cells and cells expressing FUSWT show a significant
incorporation of puromycin, while in cells expressing either
Pur-alpha or FUSMM the incorporation of puromycin is
almost absent. Then we measured puromycin incorporation
in cells expressing each mutant of FUS. As shown in
Supplementary Figure S3, we observe a prominent
reduction of puromycin incorporation in all cells with a
minimal pool of aggregated FUS in the cytoplasm. While
only a small number of cells expressing R521G and R524S
show cytoplasmic aggregates of FUS, which nevertheless
correlate with a prominent reduction of protein synthesis,
the vast majority of cells expressing R522G and P525L
shows visible aggregates associated with a robust
reduction of puromycin incorporation. Thus, either the
expression of Pur-alpha or of any FUS mutant that forms
cytoplasmic aggregates strongly reduces the rate of global
protein synthesis.
Pur-alpha associates with ribosomes. To gain more
insight into the role of Pur-alpha in the regulation of
translation we evaluated its association with ribosomal
particles. Cytoplasmic extracts from HEK293 were separated
on a linear sucrose gradient and proteins isolated from the
different fractions were analyzed by western blot. As shown in
Figure 6b a significant pool of Pur-alpha cosediments
together with 60S ribosomal subunits, with monomeric 80S
ribosomal particles and with polyribosomes, suggesting
a physical association of Pur-alpha with ribosomes.
RNAi-mediated downregulation of Pur-alpha in Drosophila
alters fly locomotion. To gather functional evidence on the
in vivo role of Pur-alpha we examined locomotion activity of
Drosophila melanogaster flies in which Pur-alpha expression
was specifically inactivated by RNAi in neurons and moto-
neurons. In Figure 7a is shown the extent of RNAi-mediated
reduction of Pur-alpha expression in two independent fly lines
(Pur-alpha_RI_1; Pur-alpha_RI_2), analyzed by western blot-
ting. The same lines were crossed with the pan neuronal
promoter 69B and the offspring, grown at 29 °C, was studied
using a Drosophila activity monitoring system. Flies of both
lines show a reduction of climbing activity, which reaches
statistical significance for Pur_alpha_RNAi_1 flies (Figure 7b,
upper panels). Correspondingly, flies grown at 29 °C and
expressing the same RNAi constructs under control of the
motoneuronal promoter D42 show climbing defects (Figure 7b,
lower panels), and again the impairment of Pur_alpha_RNAi_1
flies reaches statistical significance. Consistently, Pur_al-
pha_RNAi_1 produces a more efficient downregulation of
Pur-alpha expression compared with Pur-alpha_RI_2
(Figure 7a).
Coexpression of FUSMM and Pur-alpha exacerbates
degeneration in Drosophila. To characterize the functional
relationship between FUS and Pur-alpha in the in vivo
Drosophila model system we generated flies that coexpress
mammalian FUS and Pur-alpha proteins under UAS
promoter. Utilizing the phiC31 integrase system we produced
two different transgenic fly lines in which FUSWT and
FUSMM were inserted in the same genomic site, assuring
the same expression level (Figure 7c). With further
crosses we generated flies carrying FUSWT and Pur-alpha
transgenes, and flies carrying FUSMM and Pur-alpha. Using
the glass multimer reporter driver line we expressed these
mammalian genes in fly eye at 25 °C. Eye degeneration was
observed in flies expressing FUSWTor Pur-alpha (Figure 7d,
upper panel), while any alteration of fly eyes was observed in
flies expressing FUSMM on its own (Figure 7d, upper panel).
Combining the expression of FUSWT and Pur-alpha we do
not observe any relevant modification of the eye phenotype
produced by each single transgene. Conversely, the
coexpression of Pur-alpha and FUSMM causes stronger
eye degeneration than each single expression (Figure 7d,
Figure 5 Effect of Pur-alpha and FUSMM expression on eIF2-alpha
phosphorylation of HEK293-starved cells were transfected with HA-Pur-alpha,
Flag-FUSWT, or Flag-FUSMM. eIF2-alpha phosphorylation was evaluated by
western blotting with anti-p-eIF2-alpha antibody. In starved HEK293 cells the
expression of HA-Pur-alpha determines a strong induction of eIF2-alpha
phosphorylation as well as Flag-FUSMM, if compared with cells expressing Flag-
FUSWT or untransfected cells. The lower panel shows band quantification generated
with ImageJ analysis package. Data are presented as the ratio of phospho-eIF2-alpha
to total eIF2-alpha signal and are expressed in arbitrary units (AU). Values are
reported as mean±S.D.; n= 3. Statistical significance was evaluated with Student’s
t-test (** indicate values significantly different from controls with P-valueo0.001)
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upper panel). Parallel results were obtained expressing these
proteins under the pan neuronal driver 69B at 25 °C
(Figure 7d, lower panel): while FUSWT expression causes
early fly lethality, expressing FUSMM produces visible wing
alterations, very similar to the phenotype observed in flies
expressing Pur-alpha on its own. Again, combining the
expression of both FUSMM and Pur-alpha we obtained more
severe alterations and a strong inhibition of wing extension
(Figure 7d, lower panel). Thus, we addressed whether the
alterations due to the expression of FUSMM, Pur-alpha, or
both, correlated with an increase in neuronal cell death. We
generated Drosophila larvae expressing these proteins
in all neurons, under control of the ELAV (embryonic lethal
abnormal vision)-Gal4 (galactose-responsive transcription
Figure 6 Effect of Pur-alpha and FUSMM expression on protein synthesis. (a) Untransfected HeLa cells or cells transfected with HA-Pur-alpha, Flag-FUSWT, or
Flag-FUSMM were treated with puromycin. Untransfected cells are shown in the first row, while cells transfected with HA-Pur-alpha are in the second row. Cells with higher
expression of Pur-alpha (transfected cells) show no incorporation of puromycin, compared with untransfected cells of the same field. Puromycin incorporation was detected by
immunofluorescence with anti-puromycin antibody. Cells were also labeled by immunofluorescence with anti-Pur-alpha and anti-Flag antibodies (bars= 10 μm). (b) Cytoplasmic
extract from HEK293 cells was separated by ultracentrifugation on a linear sucrose gradient. Eleven fractions were collected monitoring the absorbance at 260 nm and the pellet
containing polyribosomes was pooled to the first fraction. The upper panel shows the absorbance profile with the position of ribosomal subunits and monomer indicated. Proteins
purified from the fractions were analyzed by western blot with the indicated antibodies
Pur-alpha inhibits translation and modulates FUS
M Di Salvio et al
7
Cell Death and Disease
Figure 7 In vivo role of Pur-alpha in Drosophila melanogaster. (a) RNAi mediated downregulation of Pur-alpha in all Drosophila tissues by the expression
of Pur_alpha_RNAi_1 and Pur_alpha_RNAi_2 RNAi under control of the ubiquitous driver tubulin-GAL4. Total extracts from RNAi expressing flies and control animals were
separated by SDS-PAGE and the extent of Pur-alpha downregulation was evaluated by western blotting with an anti-Pur-alpha antibody. (b) The same RNAi fly lines of (a) were
crossed at 29 °C with the pan neuronal driver 69B (upper panels) and with the motoneuron driver D42 (lower panels). Climbing performance of each offspring is represented
by plotting the total number of climbing events for each fly of the group. Numbers of climbing events for all flies of the group were ascending ordered and plotted. Statistical
significance was evaluated with Student’s t-test (** high statistical significance, P-valueo0.001; * statistical significance, P-valueo0.05) and the averages of climbing events
in each population, with corresponding standard errors, are shown. (c) Expression level of FUSWT, FUSMM, and Pur-alpha mammalian proteins in fly eyes. Heads from flies
expressing the transgenes under GMR were separated and homogenized. Protein extracts were separated on SDS-PAGE and the expression of each transgene was evaluated
by western blotting. (d) Genetic interaction of FUSMM and Pur-alpha in Drosophila eye. Eyes of flies expressing the mammalian genes under control of GMR Gal4 are shown.
FUSWT and Pur-alpha induces respectively very mild and mild eye degeneration, while expressing FUSMM does not determine any visible phenotype. A simultaneous
expression of both FUSMM and Pur-alpha causes strong eye degeneration. Pictures of flies expressing the transgenes under the pan neuronal driver 69B are shown. FUSWT
expression causes early fly lethality (not shown), while FUSMM induces an alteration of wing extension; similar unextended wings are observed in flies expressing Pur-alpha.
Expression of both FUSMM and Pur-alpha generates a more severe alteration of wing morphology. (e) Fly lines expressing FUSMM on its own, or combined with
Pur_alpha_RNAi_1, were crossed with 69B-GAL4 pan neuronal driver, at 25 °C. A negative geotaxis assay was performed to measure climbing activity of flies with different
genotypes. Averages of climbing evens are shown together with corresponding standard errors. Downregulation of Pur-alpha in neurons expressing FUSMM significatively
improves fly climbing activity. Statistical significance was evaluated with Student’s t-test (values significantly different from relative controls are indicated with two asterisk;
Po0.001)
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factor) driver, and whole mount brains from these animals were
stained with anti-active Caspase-3 antibodies (Supplementary
Figure S4). As shown in Supplementary Figure S4, we observe
a consistent labeling of active Caspase-3, a well-known marker
of cell death, in neuronal cells expressing FUSMM, Pur-alpha,
or both, while almost no staining is visualized in brains
expressing ELAV-Gal4 on its own.
Downregulation of endogenous Pur-alpha in flies
expressing FUSMM ameliorates climbing activity.
Since coexpression of both FUSMM and Pur-alpha produces
more severe phenotypes compared with the expression of
each single protein, we investigated the effect of Pur-alpha
downregulation in flies expressing FUSMM. We generated
flies expressing FUSMM on its own, or combined to
Pur_alpha_RNAi_1 construct, under the pan neuronal driver
69B-GAL4. Climbing activity of flies grown at 25 °C was
analyzed in a negative geotaxis assay (Figure 7e). Flies
expressing FUSMM and Pur_alpha_RNAi_1 constructs show
a significant improvement in climbing activity compared with
flies expressing FUSMM.
Discussion
Our results provide new evidence for a role of Pur-alpha in the
regulation of translation and SGs and, given its preferential
binding to ALS-linked FUS mutant proteins, we suggest that it
may be involved in the pathogenesis of FUS-mediated ALS.
We have shown that Pur-alpha binds specifically, in vitro
and in vivo, to the C-terminal region of FUS carrying
ALS-associated mutations, in an RNA-dependent manner
(Figure 1). We have observed that FUS and Pur-alpha are
expressed in spinal cord motoneurons (Figure 3b), and that
mutated FUS colocalizes with Pur-alpha in SGs (Figures 2a
and 3a). More interestingly, Pur-alpha strongly colocalizes
with mutated FUS in motoneurons differentiated from IPSCs
(Figure 4). According to a close connection between FUS
and Pur-alpha, we observe that either Pur-alpha or FUSMM
expression causes the upregulation of eIF2-alpha phosphor-
ylation (Figure 5), a signature of translational inhibition. In a
puromycin incorporation assay, used to quantify the global
rate of protein synthesis, we confirmed that their expression
arrests mRNA translation (Figure 6a and Supplementary
Figure S3). Consistently, through the sedimentation of
cytoplasmic extracts on a sucrose gradient we also observe
a prominent pool of Pur-alpha protein associated with free
60 S ribosomal subunits, monomeric ribosomal particles, and
polyribosomes (Figure 6b). A role of Pur-alpha in translation is
consistent with its observed association with RAR-alpha
and fragile X mental retardation protein in ribonucleoprotein
complexes containing translationally silencedmRNA,21 or with
its inhibitory activity in an in vitro assay of protein translation,
through the interaction with 18 S homologous ribosomal
RNA.22 Although several pieces of evidence point to a direct
role of Pur-alpha in the regulation protein synthesis, we cannot
rule out that it may also affect mRNA translation indirectly
through the potentiation of the stress response pathway.
Pur-alpha expression in Drosophila tissues (either eyes or
wings) exacerbates FUSMM phenotypes (Figure 7d), while
its downregulation ameliorates locomotion defects caused
by FUSMM expression (Figure 7e). Because both FUSMM
and Pur-alpha upregulate eIF2-alpha phosphorylation
(Figure 5) and inhibit puromycin incorporation (Figure 6a
and Supplementary Figure S3), we propose that FUSMM
and Pur-alpha affect parallel pathways converging on
the inhibition of protein translation. Our results from
Drosophila suggest that Pur-alpha may contribute to the
neurodegeneration caused by the cytoplasmic function of
FUS mutant proteins, and imply that particular human
genetic backgrounds, in which Pur-alpha expression is
downregulated, may play protective effects on the
pathological role of FUS. Thus we propose that the inhibition
of translation might be involved in FUS-mediated ALS.
This is in good agreement with what was recently observed in
a TDP-43 Drosophila model for ALS, in which eIF2-alpha
phosphorylation was increased by TDP-43 toxicity.23
Our results also indicate that the neurotoxicity mediated by
wild type or mutated FUS expression may occur through
different pathways. FUSWT-mediated neurodegeneration in the
eye is not affected by Pur-alpha expression, and FUSWT does
not substantially upregulate eIF2-alpha phosphorylation in
cultured cells. Conversely, FUSMM enhances Pur-alpha
neurodegeneration and promotes eIF2-alpha phosphorylation.
In addition, we observed a different degree of alteration
caused by the in vivo expression of either FUSWTor FUSMM,
with a stronger phenotype often associated with FUSWT
overexpression. While the expression of FUSWTunder control
of the pan neuronal driver 69B causes early fly lethality, FUSMM
expression, under the same conditions, induces only a wing
phenotype (Figure 7d). This is even more relevant as we
compared effects caused by transgenes inserted in the same
genomic site and that produce very similar levels of expression
(Figure 7c). Indeed, these results are in agreement with several
reports in which a severe ALS was caused by the upregulation
of wild-type FUS expression.24–26 Furthermore, we observe
different effects of wild type and mutated FUS on SGs. Cells
expressing R521G and R524S mutants, although show very
small pool of cytoplasmic protein and undetectable protein
aggregates, induce a relevant relocalization of Pur-alpha and
TIAR in SGs (Figure 3), while no relocalization is observed in
cells expressing FUSWT. Thus a minimal pool of cytoplasmic
mutated FUS may be sufficient to form SGs.
Finally, we also observed as the ablation of Pur-alpha
by RNAi in neurons and motor neurons affects, to a different
extent, locomotion activity of flies generating ALS-like
phenotypes (Figure 7b). Data are consistent with the
phenotype of Pur-alpha knockout mice that display a
continuous tremor starting at the age of 2 weeks, associated
with other major neurological disorders.12
In conclusion, we unveil a specific physical and genetic
interaction between Pur-alpha and FUS carrying ALS
causative mutations and a novel functional role of Pur-alpha
in the regulation of SGs and protein synthesis. Thus, we
suggest that Pur-alpha may contribute to the recruitment of
mutated FUS proteins in SGs, and potentiating their transla-
tional inhibitory effect, it may be actively involved in FUS
toxicity.
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Materials and Methods
Drosophila methodologies. Transgenic flies expressing Flag-FUSWT and
Flag-FUSMM were generated by the Bestgene Service Company using the phiC31
integrase system to insert each pUAST-attB vector in the second chromosome
(strain 24481). A HA-Pur-alpha transgenic fly line was produced by phiC31
integrase-mediated insertion of the pUAST-attB vector in the strain 24749, on the third
chromosome. RNAi fly lines targeting Pur-alpha gene expression (purA_RI_1,
v101363; purA_RI_2, v48249) were obtained from Vienna Drosophila Research
Center. Bloomington stock center (http://flybase.bio.indiana.edu/) provided all the Gal4
drivers utilized. Drosophila stocks and crosses were maintained on standard
Drosophila medium at 25 °C, unless otherwise indicated. Drosophila locomotion
activity was measured utilizing Drosophila Activity Monitor systems DAM2 (Trikinetics,
Waltham, MA, USA) to record the number of climbing events of each fly in 45 min,
banging the vials every 20 s. Climbing performance of each fly population (around 100
male flies 2–5 days after eclosion per genotype) was represented plotting the total
number of climbing events of each fly population. Numbers corresponding to the
climbing events of each fly of the population were ascending ordered and plotted as a
curve. Negative geotaxis assay was performed according to the standard protocols.27
DNA constructs. Full-length cDNA encoding human wild-type FUS (aa 1–526)
was subcloned in pcDNA3.0 by PCR amplification of Flag FUS originally cloned in
the pTRE2 vector.28,29 FUSMM construct, carrying four C-terminal ALS-associated
mutations (R521G, R522G, R524S, and P525L) was generated introducing
the corresponding nucleotide substitutions in the reverse PCR primer and
subcloning the mutated DNA in pcDNA3.0. Pur-alpha was PCR amplified from a rat
cDNA library and cloned in pcDNA3.0-HA.30 HA-Pur-alpha, Flag-FUSWT, and Flag-
FUSMM were subcloned in pUAST-attB vector to generate transgenic flies using the
phiC31 integrase system. All constructs made by PCR were sequence verified.
Antibodies. Sources of commercial antibodies were as follows: anti-FUS (Santa
Cruz, Dallas, TX, USA; 4H11), anti-Pur-alpha (Abcam, Cambridge, UK; ab77734),
anti-Pur-alpha (Abcam; ab79936), anti-HA (Santa Cruz; Y-11), anti-HA (Santa Cruz;
F-7), anti-Flag (Sigma-Aldrich, St. Louis, MO, USA; M2 and M2 affinity gel), anti-
Flag fluorescein isothiocyanate (FITC) conjugated (Sigma-Aldrich; M2), anti-
Phospho-eIF2-alpha (Cell Signaling Technology, Beverly, MA, USA; D9G8), anti-
eIF2-alpha (Cell Signaling Technology; D7D3), anti-cleaved caspase-3 (Cell
Signaling Technology; Asp175), anti-NeuN (Merck Millipore, Billerica, MA, USA;
A60), anti-TIAR (BD Biosciences, Erembodegem, Belgium), anti-GAPDH (Chemi-
con-Merck Millipore), anti-puromycin 3RH11 monoclonal antibody (Kerafast, Boston,
MA, USA), anti-FUS (Abcam; ab84078), anti-Islet-1/2 (DSHB, Iowa City, IA, USA;
39.4D5). Mouse monoclonal antibody specific for ribosomal protein S19 were
prepared in our laboratory.31 FITC, Rhodamine, and aminomethylcoumarin-
conjugated affinity-purified secondary anti`bodies, selected for absent cross-
reaction, were from Jackson ImmunoResearch (West Grove, PA, USA).
Biochemical miscellaneous procedures. Tissue homogenization and
GST pull-down experiments were carried out as previously described.32 Briefly, four
mouse brains were harvested in 20 ml of HB (150 mM NaCl, 20 mM Tris (pH 7.5),
1 mM DTT, 1 mM EDTA, and protease inhibitors cocktail (Roche, Mannheim,
Germany), homogenized, and the homogenate was spin at 3000 g for 5 min. Triton
X-100 to the final concentration of 1% was added to the supernatant and the extract
was incubate at 4 °C under constant rotation for 1 h. After centrifugation at 100
000 g for 45 min at 4 °C we collected the supernatant and measured protein
concentration with BCA PROTEIN ASSAY KIT (Pierce-Thermo Fisher Scientific,
Waltham, MA, USA). Twenty-five milligrams of brain Triton X-100 extract were
flowed 10 times through columns loaded with 500 μg of each GST fusion bound to
Glutathione Sepharose Fast Flow beads (GE Healthcare Life Sciences, Pittsburgh,
PA, USA).
Immunoprecipitations were performed from cell lysates generated in lysis buffer
(20 mM Tris (pH 7.5), 100 mM NaCl, 50 mM NaF, 1% Triton X-100) in the presence of
protease inhibitor cocktail (Roche) and 1 mM orthovanadate. SDS-PAGE and western
blotting were performed according to the standard protocols. Maldi-mass spectro-
metry was carried out by Telethon Proteomics Facility at the ISS (Istituto Superiore di
Sanità), directed by Marco Crescenzi, as previously described.33 In vitro translated
were prepared according to the manufacturer’s protocols (TNT Quick Coupled
Transcription/Translation Systems, Invitrogen-Thermo Fisher Scientific, Waltham,
MA, USA).
To separate polyribosomes and ribosomal subunits, HEK293 cells were collected
by scraping and then resuspended in lysis buffer (10 mM Tris-HCl (pH 7.5), 10 mM
NaCl and 10 mM MgCl2, 1 mg/ml 0.5% NP-40, aprotinin, 1 mg/ml leupeptin, 1 mg/ml
pepstatinA, and 100 mg/ml phenylmethanesulfonylfluoride). After incubation in ice for
20 min, the extract was centrifuged for 15 min in a microcentrifuge at a maximum
speed at 4 °C and the supernatant (cytoplasmic extract) was loaded onto 10–30%
linear sucrose gradient containing 30 mM Tris-HCl (pH 7.5), 100 mM NaCl and
10 mM MgCl2. Gradients were centrifuged in a Beckman SW 41 rotor for 4.5 h
at 151 000 g and collected in 11 fractions while monitoring the absorbance at 260 nm.
The pellet was resuspended in the first fraction (polyribosomes). All fractions were
precipitated with trichloroacetic acid, washed with acetone, dried, resuspended
in loading buffer, and analyzed by western blot.
Puromycin incorporation assay. HeLa cells were treated for 10 min with
10 μg/ml of puromycin at 37 ºC. After two rapid washes in phosphate-buffered
saline (PBS) cells were fixed with 4% paraformaldehyde in PBS. Blocking and
antibody-staining (3RH11 antibody; Kerafast) were performed in PBS, 1% bovine
serum albumin (BSA) buffer.
Cell culture and immunofluorescence. HeLa and HEK293 cell lines were
originally purchased from ATCC (Teddington, UK). NSC-34 cells were originally
obtained from N. R. Cashman (University of Toronto, Toronto, ON, Canada).
Transfection experiments were performed using Lipofectamine 2000 (Invitrogen-
Thermo Fisher Scientific) according to the manufacturer’s protocol. For immuno-
fluorescence experiments cells were grown on glass coverslips and fixed in 4%
paraformaldehyde in 60mM phosphate buffer (pH 7.4). Mouse spinal cord sections
were blocked and immunostained in BDB (BSA dilution buffer) containing 3% BSA,
0.3% Triton X-100, 20 mM phosphate buffer (pH 7.4), and 450 mM NaCl. Whole mount
Drosophila brain were dissected and stained according to a standard protocol.34
Immunofluorescence analysis was carried out using Zeiss LSM 510 confocal
microscopy, an Axioplan (Carl Zeiss, Jena, Germany) epi-fluorescent microscope
equipped with CCD camera (Photometrics, Tucson, AZ, USA) and a Leica SP2
confocal microscope. Fluorescence images were processed using Adobe Photoshop.
Generation and maintenance of human iPSCs. Skin biopsies of
informed donor ALS patients were used to generate dermal fibroblasts cultured in
fibroblast basal medium (Lonza, Basel, Switzerland) containing 15% feta bovine serum
(FBS), 1 × L-Glu, 1 × penicillin–streptomycin (all from Sigma-Aldrich). ALS and control
fibroblasts were infected in serum-free conditions and in the presence of 4 mg/ml
polybrene with the lentiviral vector hSTEMCCA,35 which carries the four
reprogramming factors OCT4, SOX2, KLF4, and cMYC in a single polycistronic
unit. Seven days after infection fibroblasts were seeded on a feeder layer of mitomycin
C-treated primary mouse embryonic fibroblasts (PMEF-CF; Millipore) and the
next day the medium was changed in HUESM (DMEM-F12+Glutamax,
Life Technologies-Thermo Fisher Scientific, Waltham, MA, USA; 20% knockout serum
replacement, Life Technologies-Thermo Fisher Scientific; 1 × non-essential aminoa-
cids, NEAA, Life Technologies-Thermo Fisher Scientific; 1 × penicillin–streptomycin,
0.1 mM β-mercaptoethanol, Gibco-Thermo Fisher Scientific, Waltham, MA, USA)
supplemented with basic fibroblast growth factor (10 ng/ml; BD Biosciences). Twenty
days after infection the medium was replaced with Nutristem-XF (Biological Industries,
Beit-Haemek, Israel). iPSC colonies were manually picked, fragmented, and plated on
PMEF-CF coated wells. Established iPSC lines were maintained in Nutristem-XF on
hESC-qualified Matrigel-coated plates (BD Biosciences) and passaged every 4–
5 days with 1 mg/ml Dispase (Gibco-Thermo Fisher Scientific).
Generation of iPSCs carrying the FUS-P525L mutation by
transcription activator-like effector nucleases. Using a genome
editing approach based on transcription activator-like effector nucleases (TALENs)
we introduced the P525L mutation in the endogenous FUS locus of an iPSC-WT
line. The TALE-TN software (available at https://tale-nt.cac.cornell.edu ) provided the
sequence of a TALEN pair specific for exon 15 in the FUS locus. We generated a
homology directed repair (HDR) donor construct including the P525L mutation and
a selection cassette containing an independent promoter (PGK) that drives the
expression of the PUΔTK bifunctional protein,36 which in turn confers resistance to
puromycin and sensitivity to ganciclovir (GCV). After co-transfection of this construct
with the FUS C-term TALENs, we isolated individual puromycin-resistant clones.
HDR stimulated by TALENs promoted the insertion of the selection cassette flanked
by the enhanced piggyBac (ePB) terminal repeats. First we selected clones
containing the cassette in both FUS alleles, which represented a homozygous
mutant. We transfected such cells with a modified PB transposase, which was
competent for excision but not for the re-integration of the cassette. iPSCs retaining
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the exogenous cassette were counter-selected by GCV. Finally we isolated
individual GCV-resistant clones and the presence of the homozygous P525L
mutation was confirmed by sequencing.
Differentiation of iPSCs into neural cells. iPSCs around passage 10–20
were plated in HUESM supplemented with SMAD inhibitors (SB/DM; 10 μM
SB431542 and 2.5 μM Dorsomorphin, both from Miltenyi Biotec, Bologna, Italy) and
were considered as day 0 of differentiation (D0). From D4, in the presence of SB/DM,
the medium was gradually replaced with N2M (DMEM-F12; 1 × N2 Supplement, Life
Technologies-Thermo Fisher Scientific; 1 × NEAA, Life Technologies-Thermo Fisher
Scientific; 2 μg/ml heparin, Sigma-Aldrich). We started at D4 with 75% HUESM and
25% N2M that reached 25% HUESM and 75% N2M at D8. From D10 to D14,
differentiating neural progenitors were cultured in N2M supplemented with 0.1 μM all-
trans retinoic acid (RA; Sigma-Aldrich). At D14 neural rosettes were manually
detached to generate floating neurospheres, maintained in N2M supplemented with
0.1 μM RA and 1 μM purmorphamine (sc-202705; Santa Cruz). At D28 neurospheres
were plated in poly-L-lysine (Sigma-Aldrich) and Natural Mouse Laminin (Invitrogen-
Thermo Fisher Scientific) coated glass coverslips for immunostaining, in N2M
supplemented with 10% FBS. The day after, the medium was replaced with N2M
supplemented with 10 ng/ml brain-derived neurotrophic factor, 10 ng/ml glial cell line-
derived neurotrophic factor, and 10 ng/ml insulin-like growth factor (all from
PreproTech, London, UK), 1 μM cAMP and 200 ng/ml L-ascorbic acid (both from
Sigma-Aldrich), 0.05 μM RA and 0.5 μM purmorphamine. Motoneuronal cells were
fixed for immunostaining at day 34.
Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. We thank Marcello Ceci, Monica Nencini, and Simona
Rossi for their help and Marco Crescenzi (ISS) for mass spectrometry determinations.
This work was supported by the Italian Foundation for ALS research (AriSLA)
(FUSinteractor to GC, OligoALS to MTC, and FUSMALS to MC); the Bruno and Ilse
Frick Foundation for ALS research 2012 Award (to both GC and MTC); the Ministry of
Economy to the CNR for the project FaReBio di Qualità (GC); the Ministry of Health
(RF-2010-2309849 to MC); ERC-2013 – (AdG 340172–MUNCODD), IIT 'SEED',
Epigen-Epigenomics Flagship Project, HFSP (RGP0009/2014), and PRIN (IB).
1. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics.
Nat Neurosci 2014; 17: 17–23.
2. Vance C, Rogelj B, Hortobagyi T, De Vos KJ, Nishimura AL, Sreedharan J et al. Mutations in
FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6.
Science 2009; 323: 1208–1211.
3. Kwiatkowski Jr TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C et al.
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral
sclerosis. Science 2009; 323: 1205–1208.
4. Da Cruz S, Cleveland DW. Understanding the role of TDP-43 and FUS/TLS in ALS
and beyond. Curr Opin Neurobiol 2011; 21: 904–919.
5. Zhang ZC, Chook YM. Structural and energetic basis of ALS-causing mutations in the
atypical proline-tyrosine nuclear localization signal of the Fused in Sarcoma protein (FUS).
Proc Natl Acad Sci USA 2012; 109: 12017–12021.
6. Dormann D, Rodde R, Edbauer D, Bentmann E, Fischer I, Hruscha A et al. ALS-associated
fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J
2010; 29: 2841–2857.
7. Graebsch A, Roche S, Niessing D. X-ray structure of Pur-alpha reveals a Whirly-like fold and
an unusual nucleic-acid binding surface. Proc Natl Acad Sci USA 2009; 106: 18521–18526.
8. Kanai Y, Dohmae N, Hirokawa N. Kinesin transports RNA: isolation and characterization of
an RNA-transporting granule. Neuron 2004; 43: 513–525.
9. White MK, Johnson EM, Khalili K. Multiple roles for Puralpha in cellular and viral regulation.
Cell Cycle 2009; 8: 1–7.
10. Darbinian N, Cui J, Basile A, Del Valle L, Otte J, Miklossy J et al. Negative regulation
of AbetaPP gene expression by pur-alpha. J Alzheimers Dis 2008; 15: 71–82.
11. Johnson EM, Kinoshita Y, Weinreb DB, Wortman MJ, Simon R, Khalili K et al. Role of Pur
alpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J Neurosci
Res 2006; 83: 929–943.
12. Hokkanen S, Feldmann HM, Ding H, Jung CK, Bojarski L, Renner-Muller I et al. Lack of
Pur-alpha alters postnatal brain development and causes megalencephaly. Hum Mol Genet
2012; 21: 473–484.
13. Sareen D, O'Rourke JG, Meera P, Muhammad AK, Grant S, Simpkinson M et al. Targeting
RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat
expansion. Sci Transl Med 2013; 5: 208ra149.
14. Xu Z, Poidevin M, Li X, Li Y, Shu L, Nelson DL et al. Expanded GGGGCC repeat RNA
associated with amyotrophic lateral sclerosis and frontotemporal dementia causes
neurodegeneration. Proc Natl Acad Sci USA 2013; 110: 7778–7783.
15. Shelkovnikova TA, Robinson HK, Troakes C, Ninkina N, Buchman VL. Compromised paraspeckle
formation as a pathogenic factor in FUSopathies. Hum Mol Genet 2014; 23: 2298–2312.
16. Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M et al.Mutant induced
pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal
cell-specific vulnerability. Proc Natl Acad Sci USA 2012; 109: 5803–5808.
17. Kedersha NL, Gupta M, Li W, Miller I, Anderson P. RNA-binding proteins TIA-1 and TIAR link
the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. J Cell Biol
1999; 147: 1431–1442.
18. Kedersha N, Cho MR, Li W, Yacono PW, Chen S, Gilks N et al. Dynamic shuttling of TIA-1
accompanies the recruitment of mRNA to mammalian stress granules. J Cell Biol 2000; 151:
1257–1268.
19. Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor
protein synthesis. Nat Methods 2009; 6: 275–277.
20. David A, Dolan BP, Hickman HD, Knowlton JJ, Clavarino G, Pierre P et al. Nuclear
translation visualized by ribosome-bound nascent chain puromycylation. J Cell Biol 2012;
197: 45–57.
21. Chen N, Onisko B, Napoli JL. The nuclear transcription factor RARalpha associates with
neuronal RNA granules and suppresses translation. J Biol Chem 2008; 283: 20841–20847.
22. Gallia GL, Darbinian N, Jaffe N, Khalili K. Single-stranded nucleic acid-binding protein,
Pur alpha, interacts with RNA homologous to 18 S ribosomal RNA and inhibits translation
in vitro. J Cell Biochem 2001; 83: 355–363.
23. Kim HJ, Raphael AR, Ladow ES, McGurk L, Weber RA, Trojanowski JQ et al. Therapeutic
modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral
sclerosis disease models. Nat Genet 2014; 46: 152–160.
24. Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B et al.
Overexpression of human wild-type FUS causes progressive motor neuron degeneration in
an age- and dose-dependent fashion. Acta Neuropathol 2013; 125: 273–288.
25. Sabatelli M, Moncada A, Conte A, Lattante S, Marangi G, Luigetti M et al. Mutations in the 3'
untranslated region of FUS causing FUS overexpression are associated with amyotrophic
lateral sclerosis. Hum Mol Genet 2013; 22: 4748–4755.
26. Xia R, Liu Y, Yang L, Gal J, Zhu H, Jia J. Motor neuron apoptosis and neuromuscular junction
perturbation are prominent features in a Drosophila model of Fus-mediated ALS.
Mol Neurodegener 2012; 7: 10.
27. Nichols CD, Becnel J, Pandey UB. Methods to assay Drosophila behavior. J Vis Exp 2012;
61: 3791–3795.
28. Cozzolino M, Pesaresi MG, Gerbino V, Grosskreutz J, Carri MT. Amyotrophic lateral
sclerosis: new insights into underlying molecular mechanisms and opportunities for
therapeutic intervention. Antioxid Redox Signal 2012; 17: 1277–1330.
29. Gerbino V, Carri MT, Cozzolino M, Achsel T, Mislocalised FUS. mutants stall spliceosomal
snRNPs in the cytoplasm. Neurobiol Dis 2013; 55: 120–128.
30. Cestra G, Toomre D, Chang S, De Camilli P. The Abl/Arg substrate ArgBP2/nArgBP2
coordinates the function of multiple regulatory mechanisms converging on the actin
cytoskeleton. Proc Natl Acad Sci USA 2005; 102: 1731–1736.
31. Chiocchetti A, Gibello L, Carando A, Aspesi A, Secco P, Garelli E et al. Interactions between
RPS19, mutated in Diamond-Blackfan anemia, and the PIM-1 oncoprotein. Haematologica
2005; 90: 1453–1462.
32. Slepnev VI, Ochoa GC, Butler MH, Grabs D, De Camilli P. Role of phosphorylation in
regulation of the assembly of endocytic coat complexes. Science 1998; 281: 821–824.
33. Lalle M, Camerini S, Cecchetti S, Sayadi A, Crescenzi M, Pozio E. Interaction network of the
14-3-3 protein in the ancient protozoan parasite Giardia duodenalis. J Proteome Res 2012;
11: 2666–2683.
34. Wu JS, Luo L. A protocol for dissecting Drosophila melanogaster brains for live imaging or
immunostaining. Nat Protoc 2006; 1: 2110–2115.
35. Somers A, Jean JC, Sommer CA, Omari A, Ford CC, Mills JA et al. Generation of
transgene-free lung disease-specific human induced pluripotent stem cells using a single
excisable lentiviral stem cell cassette. Stem Cells 2010; 28: 1728–1740.
36. Chen YT, Bradley A. A new positive/negative selectable marker, puDeltatk, for use in
embryonic stem cells. Genesis 2000; 28: 31–35.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
Creative Commons license, users will need to obtain permission from
the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
Pur-alpha inhibits translation and modulates FUS
M Di Salvio et al
11
Cell Death and Disease
